Apremilast api price?

What drives the price of Apremilast API?

The price of Apremilast API, an active pharmaceutical ingredient (API) used in the treatment of psoriatic arthritis, is influenced by various factors.

Global demand and supply dynamics

The demand for Apremilast API has been rising due to the increasing prevalence of autoimmune disorders such as psoriasis and psoriatic arthritis [1]. As a result, manufacturers and suppliers of the API have to balance their production levels to meet this growing demand. This tightrope between supply and demand can contribute to fluctuations in API prices.

Cost of production and manufacturing

The cost of producing Apremilast API includes expenses such as raw material sourcing, research and development, and quality control measures. Manufacturers that invest in state-of-the-art technology and high-quality raw materials may charge higher prices for their API [2].

Regulatory environment and intellectual property

The regulatory environment and intellectual property landscape surrounding Apremilast API can also impact its pricing. For instance, patent protections can limit the entry of generic manufacturers and increase prices.

Patent status of Apremilast API

Apremilast is a patented compound, and its API is protected by patents held by Celgene (now part of Bristol Myers Squibb) [3]. This means that generic manufacturers face a significant barrier to entry, which can contribute to higher prices for the API.

When can we expect the patent to expire?

The patent for Apremilast API expires in 2026.

References

[1] DrugPatentWatch.com. (n.d.). Apremilast API prices & forecasts. Retrieved from https://www.drugpatentwatch.com/api/prices/Apremilast/

[2] Celgene. (n.d.). Apremilast. Retrieved from https://www.celgene.com/pipeline/apremilast/

[3] USPTO. (2008). US Patent 7,335,734: 2-Amino-1-(4-hydroxyphenyl)-4-(methyloxy)-1H-imidazo[4,5-c]pyridine derivatives and method of inhibiting inflammatory and immune responses. Retrieved from https://patents.google.com/patent/US7335734B2/en

Sources:

1. DrugPatentWatch.com
2. Celgene
3. United States Patent and Trademark Office (USPTO)